Department of Family and Community Health; University of Pennsylvania School of Nursing; Philadelphia, PA USA; LDI Center for Health Incentives and Behavioral Economics; University of Pennsylvania; Philadelphia, PA USA.
Center for Health Equity Research and Promotion; Philadelphia VA Medical Center; Philadelphia, PA USA; Penn Medicine Center for Health Care Innovation; Philadelphia, PA USA.
Hum Vaccin Immunother. 2013 Dec;9(12):2674-5. doi: 10.4161/hv.26676. Epub 2013 Oct 2.
Herd immunity against vaccine-preventable diseases is a public good because it is both non-excludable (meaning that there is no way to exclude people from using it) and non-rivalrous (meaning that one person's use does not limit or restrict others' use). Like other public goods, such as lighthouses, street lights and national defense, herd immunity is vulnerable to the "free rider" problem. We discuss four conventional responses to the free rider problem (participation mandates, exclusion, incentives, and social norms) and highlight how a public good perspective can inform the design of interventions to increase vaccine acceptance.
群体免疫对预防疫苗可预防疾病来说是一种公共产品,因为它具有非排他性(即无法将人群排除在使用之外)和非竞争性(即一个人的使用不会限制或限制他人的使用)。与其他公共产品(如灯塔、路灯和国防)一样,群体免疫容易受到“搭便车”问题的影响。我们讨论了应对搭便车问题的四种传统方法(参与授权、排除、激励和社会规范),并强调了公共产品视角如何为提高疫苗接受度的干预措施设计提供信息。